
Published On: Oct 2022
Published On: Oct 2022
At 4.8% CAGR, the SAM Doxorubicin Market is projected to be worth US$ 86.34 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the SAM doxorubicin market was valued at US$ 65.06 million in 2022 and is expected to reach US$ 86.34 million by 2028, registering an annual growth rate of 4.8% from 2022 to 2028. Increasing approval of generic products and increasing preference for chemotherapy are the critical factors attributed to the market expansion.
Cancer treatment has yielded better results, but access to medicines has become a problem across the region, especially in low- and middle-income countries. However, replacing it with a generic drug can save significantly. The doxorubicin market is characterized by the presence of large and small companies. Players are taking up product launches, regional expansions, and technological advancements to increase their market share. Continuous innovations and technological advancements result in safer and more effective doxorubicin drugs, increasing acceptance among patients and medical societies. Several developments have taken place in the recent years. For instance, in September 2020, Zydus Cadila received final approval for the commercialization of its generic Doxorubicin Hydrochloride Liposome Injection. Further, in September 2018, Hikma Pharmaceuticals PLC launched Adriamycin (DOXOrubicin HCl) for Injection as a part of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node association following resection of primary breast cancer. Thus, approval of generic substitution for frequently used chemotherapy drugs, such as doxorubicin, in treating common cancers has a vast potential to increase significant cost savings and rising access to cancer treatments in several countries across the region.
On the contrary, potential side-effects associated with doxorubicin hurdles the growth of SAM doxorubicin market.
Key players dominating the SAM doxorubicin market are Accord Healthcare; Baxter International Inc.; Cipla Inc.; Dr. Reddy's Laboratories; Janssen Pharmaceuticals (Johnson & Johnson Services, Inc.); Meiji Holdings Co., Ltd.; Novartis AG; Pfizer Inc.; Sun Pharmaceutical Industries Ltd; and Zydus Cadila among others.
Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com